These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35359635)

  • 21. Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment.
    Prezioso C; Ciotti M; Brazzini G; Piacentini F; Passerini S; Grimaldi A; Landi D; Nicoletti CG; Zingaropoli MA; Iannetta M; Altieri M; Conte A; Limongi D; Marfia GA; Ciardi MR; Mastroianni CM; Palamara AT; Moens U; Pietropaolo V
    J Clin Med; 2022 Jan; 11(2):. PubMed ID: 35054041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
    Diotti RA; Capra R; Moiola L; Caputo V; De Rossi N; Sangalli F; Martinelli V; Burioni R; Clementi M; Mancini N
    Viruses; 2016 May; 8(5):. PubMed ID: 27164128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
    Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
    Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding polyomavirus CNS disease - a perspective from mouse models.
    Ayers KN; Carey SN; Lukacher AE
    FEBS J; 2022 Oct; 289(19):5744-5761. PubMed ID: 34145975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High levels of endothelial ICAM-1 prohibit natalizumab mediated abrogation of CD4
    Soldati S; Bär A; Vladymyrov M; Glavin D; McGrath JL; Gosselet F; Nishihara H; Goelz S; Engelhardt B
    J Neuroinflammation; 2023 May; 20(1):123. PubMed ID: 37221552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COS-7 cells are a cellular model to monitor polyomavirus JC miR-J1-5p expression.
    Agostini S; Mancuso R; Costa AS; Guerini FR; Clerici M
    Mol Biol Rep; 2020 Nov; 47(11):9201-9205. PubMed ID: 33085050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    Chisari CG; Comi G; Filippi M; Paolicelli D; Iaffaldano P; Zaffaroni M; Brescia Morra V; Cocco E; Marfia GA; Grimaldi LM; Inglese M; Bonavita S; Lugaresi A; Salemi G; De Luca G; Cottone S; Conte A; Sola P; Aguglia U; Maniscalco GT; Gasperini C; Ferrò MT; Pesci I; Amato MP; Rovaris M; Solaro C; Lus G; Maimone D; Bergamaschi R; Granella F; Di Sapio A; Bertolotto A; Totaro R; Vianello M; Cavalla P; Bellantonio P; Lepore V; Patti F;
    J Neurol; 2022 Feb; 269(2):933-944. PubMed ID: 34181077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type O blood group associates with higher anti-JC polyomavirus antibody levels.
    Frenken P; Hartung HP; Olsson T; Adams O; Warnke C
    Brain Behav; 2021 Aug; 11(8):e2298. PubMed ID: 34291599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyomavirus detection in multiple sclerosis patients under natalizumab therapy: Profile and frequency of urinary shedding.
    Nali LH; Fink MC; do Olival GS; Moraes L; Callegaro D; Tilbery CP; Vidal JE; Sumita LM; de Oliveira AC; Romano CM
    J Med Virol; 2017 Mar; 89(3):528-534. PubMed ID: 27464945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis.
    Ciardi MR; Zingaropoli MA; Iannetta M; Prezioso C; Perri V; Pasculli P; Lichtner M; d'Ettorre G; Altieri M; Conte A; Pietropaolo V; Mastroianni CM; Vullo V
    Virol J; 2020 Feb; 17(1):23. PubMed ID: 32046748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The human JC polyomavirus (JCPyV): virological background and clinical implications.
    Hirsch HH; Kardas P; Kranz D; Leboeuf C
    APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
    Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
    Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.
    Prezioso C; Grimaldi A; Landi D; Nicoletti CG; Brazzini G; Piacentini F; Passerini S; Limongi D; Ciotti M; Palamara AT; Marfia GA; Pietropaolo V
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
    Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
    CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
    Spadaro M; Caldano M; Marnetto F; Lugaresi A; Bertolotto A
    J Neuroinflammation; 2015 Aug; 12():146. PubMed ID: 26259673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.